A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Wall Street sees plenty of growth ahead, projecting an 8.2% jump in sales for 2025 as new products gain traction ... dollar markets, Vertex offers a compelling mix of stability and upside potential.

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...